I am a
Home I AM A Search Login

Papers of the Week


2022 Jun 29


EBioMedicine


81

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females.

Authors

Marchevsky N G, Li G, Aley P, Costa Clemens S A, Barrett J R, Belij-Rammerstorfer S, Bibi S, Clutterbuck E, Dold C, Felle S, Flaxman A, Folegatti P, Jenkin D, Gilbert S, Kelly S, Lambe T, Plested E, Ramasamy M, Singh N, Smith H, et al.
EBioMedicine. 2022 Jun 29; 81:104128.
PMID: 35779491.

Abstract

There are known differences in vaccine reactogenicity and immunogenicity by sex. Females have been shown to report greater reactogenicity and generate higher humoral and cellular immune responses than males following vaccination with several different vaccines. Whether this is also the case for COVID-19 vaccines is currently unknown, as COVID-19 vaccine study data disaggregated by sex are not routinely reported. Therefore, we have assessed the influence of sex on reactogenicity, immunogenicity and efficacy of COVID-19 vaccine ChAdOx1 nCoV-19.